Table 2. . Summary of studies and data.
| Study (year) | NSCLC population | Phase | Treatment | Treatment line | Efficacy | Ref. |
|---|---|---|---|---|---|---|
| Quoix et al. (2016) | Non-Sq and Sq | III | Gem/cis or pem/cis or pac/carbo ± TG 4010 or placebo | First line | PFS: HR: 0.74 (95% CI: 0.55–0.98); p = 0.019 | [14] |
| Lynch et al. (2012) | Non-Sq and Sq | II | Pac/carbo + ipi or placebo | First line | irPFS: HR: 0.72 (95% CI: 0.50–1.06); p = 0.05 | [22] |
| Rizvi et al. (2016) | Non-Sq and Sq | I | Gem/cis, pem/cis or pac/carbo + nivo | First line | ORR: 33%, 47% and 43% OS at 2 years: 25%, 33% and 62% |
[23] |
| Liu et al. (2015) | Non-Sq and Sq | I | Pac/carbo, Pem/carbo or nab-pac/carbo + atezo | First line | ORR: 60%, 75% and 62% | [24] |
| Papadimitrakopoulou et al. (2015) | Non-Sq and Sq | I | Pac/carbo or pem/carbo + pembro | First line | ORR: 28% and 58% | [25] |
| Rizvi et al. (2014) | EGFR+ non-Sq | I | Nivo + erlotinib | First line | ORR: 19% | [26] |
| Antonia et al. (2016) | Non-Sq and Sq | I | Durva + treme | Any line | ORR: 23% | [27] |
| Patnaik et al. (2015) | Non-Sq and Sq | I | Pembro + ipi | Any line | ORR: 55% | [28] |
| Antonia et al. (2014) | Non-Sq and Sq | I | Nivo + ipi | First line | ORR: 22% | [29] |
| Hellmann et al. (2016) | Non-Sq and Sq | I | Nivo + ipi | First line | ORR: 39% and 47% | [30] |
Atezo: Atezolizumab; Carbo: Carboplatin; Cis: Cisplatin; Durva: Durvalumab; Gem: Gemcitabine; HR: Hazard ratio; Ipi: Ipilimumab; irPFS: Immune-related progression-free survival; Nab-pac: Nab-paclitaxel; Nivo: Nivolumab, ORR: Objective response rate; OS: Overall survival; Pac: Paclitaxel; Pem: Pemetrexed; Pembro: Pembrolizumab; PFS: Progression-free survival; Sq: Squamous; Treme: Tremelimumab.